antiviral

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #90, Dr. Griffin covers FDA expansion for booster doses, 3 more at home antigen tests approved by FDA, immune correlates analysis of mRNA-1273 vaccine, risk for stillbirth, PROVENT prophylaxis trial results, fluvoxamine recommendations, advice on molnupiravir, automated text messaging service for monitoring illness, and long COVID-19 after vaccination and infection. Click …

TWiV 834: COVID-19 clinical update #90 with Dr. Daniel Griffin Read More »

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #89, Dr. Griffin reviews upcoming meeting on FDA emergency use authorization for molnupiravir, 25% of US cases in children, reinfection associates with presence of antibodies, national surveillance for acute flaccid myelitis in the US, and monoclonal antibody treatment of infection in vaccinated, high-risk individuals. Click arrow to playDownload TWiV 831 (20 MB .mp3, …

TWiV 831: COVID-19 clinical update #89 with Dr. Daniel Griffin Read More »

TWiV 828: COVID-19 clinical update #88 with Dr. Daniel Griffin

This Week in Virology / By Vincent Racaniello

In COVID-19 clinical update #88, Dr. Griffin covers vaccine protection among US veterans, absence of long COVID in vaccinated who are infected, single dose of REGEN-COV monoclonal antibody cocktail provides long term protection, and Pfizer protease inhibitor Paxlovid is 89% effective in preventing hospitalization or death. Show notes at microbe.tv/twiv

Pills for COVID-19

4 Comments / Basic virology, Information / By Vincent Racaniello

Multiple vaccines have been developed that have made substantial contributions to controlling the COVID-19 pandemic, but where are the antivirals? Only repurposed drugs have been used and not with much success. That situation seems about to change with the authorization of drugs that target the RNA polymerase (Molnupiravir) and a viral protease (Paxlovid). Molnupiravir is …

Pills for COVID-19 Read More »

An antiviral to prevent or treat SARS-CoV-2 infection

4 Comments / Basic virology / By Vincent Racaniello

Vaccine development has far outpaced antiviral discovery for COVID-19. Hydroxychloroquine was a disaster, and the repurposed remdesivir, which must be administered intravenously, has modest effect when given to hospitalized patients. The situation is unfortunate because antiviral drugs may be used to either prevent infection (prophylactic) or treat infection (therapeutic). A promising antiviral drug candidate is …

An antiviral to prevent or treat SARS-CoV-2 infection Read More »

A mouse model for COVID-19

3 Comments / Uncategorized / By Vincent Racaniello

Small animal models (mice, ferrets, hamsters) are essential for understanding how SARS-CoV-2 causes disease and for pre-clinical evaluation of vaccines and antiviral therapeutics. One promising model has been developed by modifying SARS-CoV-2 so that it binds to murine ACE2. Laboratory mice cannot be infected with SARS-CoV-2 because the viral spike glycoprotein (illustrated) does not bind …

A mouse model for COVID-19 Read More »

Start typing and press enter to search